Xspray Pharma AB (publ) (XSPRAY.ST)
SEK 26.5
(1.73%)
SEK 26.5
(1.73%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -180.76 Million SEK | -35.84% |
| 2022 | -133.07 Million SEK | -35.85% |
| 2021 | -97.95 Million SEK | -83.24% |
| 2020 | -53.45 Million SEK | -16.96% |
| 2019 | -45.7 Million SEK | -96.86% |
| 2018 | -23.21 Million SEK | -74.86% |
| 2017 | -13.27 Million SEK | -227.12% |
| 2016 | -4.05 Million SEK | 66.42% |
| 2015 | -12.08 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -67.33 Million SEK | -19.23% |
| 2024 Q2 | -53.8 Million SEK | 20.09% |
| 2023 FY | -209.82 Million SEK | -57.68% |
| 2023 Q3 | -39.23 Million SEK | 23.46% |
| 2023 Q1 | -35.38 Million SEK | 36.34% |
| 2023 Q2 | -51.26 Million SEK | -44.85% |
| 2023 Q4 | -56.47 Million SEK | -43.94% |
| 2022 FY | -133.07 Million SEK | -35.85% |
| 2022 Q4 | -55.58 Million SEK | -91.72% |
| 2022 Q2 | -29.21 Million SEK | -51.49% |
| 2022 Q3 | -28.99 Million SEK | 0.74% |
| 2022 Q1 | -19.28 Million SEK | 63.12% |
| 2021 Q1 | -14.17 Million SEK | 7.3% |
| 2021 FY | -97.95 Million SEK | -83.24% |
| 2021 Q2 | -17.28 Million SEK | -21.95% |
| 2021 Q3 | -14.2 Million SEK | 17.81% |
| 2021 Q4 | -52.27 Million SEK | -267.91% |
| 2020 Q4 | -15.29 Million SEK | -29.49% |
| 2020 FY | -53.45 Million SEK | -16.96% |
| 2020 Q3 | -11.81 Million SEK | 24.48% |
| 2020 Q2 | -15.63 Million SEK | -45.97% |
| 2020 Q1 | -10.71 Million SEK | 28.84% |
| 2019 Q2 | -11.38 Million SEK | -32.11% |
| 2019 Q1 | -8.61 Million SEK | 17.95% |
| 2019 Q3 | -10.7 Million SEK | 5.95% |
| 2019 FY | -45.7 Million SEK | -96.86% |
| 2019 Q4 | -15.05 Million SEK | -40.66% |
| 2018 Q4 | -10.5 Million SEK | -141.1% |
| 2018 Q1 | -1.59 Million SEK | 66.69% |
| 2018 FY | -23.21 Million SEK | -74.86% |
| 2018 Q2 | -6.76 Million SEK | -323.93% |
| 2018 Q3 | -4.35 Million SEK | 35.63% |
| 2017 Q4 | -4.79 Million SEK | -68.96% |
| 2017 Q1 | -6.33 Million SEK | -164.52% |
| 2017 Q2 | 682 Thousand SEK | 110.77% |
| 2017 FY | -13.27 Million SEK | -227.12% |
| 2017 Q3 | -2.83 Million SEK | -515.84% |
| 2016 Q1 | -3.57 Million SEK | 0.0% |
| 2016 FY | -4.05 Million SEK | 66.42% |
| 2016 Q3 | -6.72 Million SEK | -88.08% |
| 2016 Q4 | 9.81 Million SEK | 245.98% |
| 2016 Q2 | -3.57 Million SEK | 0.0% |
| 2015 FY | -12.08 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Simris Alg AB (publ) | -36.63 Million SEK | -393.422% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 43.776% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 41.769% |
| Xintela AB (publ) | -57.23 Million SEK | -215.813% |
| Active Biotech AB (publ) | -46.48 Million SEK | -288.876% |
| Amniotics AB (publ) | -29.07 Million SEK | -521.762% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -1134.734% |
| BioArctic AB (publ) | 252.64 Million SEK | 171.55% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 52.974% |
| Camurus AB (publ) | 532.35 Million SEK | 133.956% |
| Cantargia AB (publ) | -290.01 Million SEK | 37.671% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -797.587% |
| CombiGene AB (publ) | -36.3 Million SEK | -397.904% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -23.333% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -957.335% |
| Genovis AB (publ.) | 54.22 Million SEK | 433.367% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -57.087% |
| Mendus AB (publ) | -100.65 Million SEK | -79.598% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -333.666% |
| Intervacc AB (publ) | -93.57 Million SEK | -93.168% |
| Kancera AB (publ) | -65.04 Million SEK | -177.92% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -5057.347% |
| LIDDS AB (publ) | -40.67 Million SEK | -344.424% |
| Lipum AB (publ) | -37.25 Million SEK | -385.223% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -1361.2% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 1103.748% |
| NextCell Pharma AB | -43.17 Million SEK | -318.708% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1036.744% |
| Saniona AB (publ) | -81.06 Million SEK | -122.988% |
| Ziccum AB (publ) | -21.56 Million SEK | -738.428% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -1002.158% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 27.399% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -21292.308% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -1065.324% |
| Corline Biomedical AB | -1.78 Million SEK | -10009.899% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | -0.0% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -226.191% |
| Aptahem AB (publ) | -10.1 Million SEK | -1688.909% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -34.281% |
| Fluicell AB (publ) | -26.87 Million SEK | -572.514% |
| Biovica International AB (publ) | -126.07 Million SEK | -43.381% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -325.279% |
| AcouSort AB (publ) | -17.48 Million SEK | -933.711% |
| Abliva AB (publ) | -96.54 Million SEK | -87.228% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 44.346% |
| 2cureX AB (publ) | -36.36 Million SEK | -397.112% |
| I-Tech AB | 24.43 Million SEK | 839.779% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 77.075% |
| Cyxone AB (publ) | -21.66 Million SEK | -734.518% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -70.589% |
| Biosergen AB | -27.26 Million SEK | -562.993% |
| Nanologica AB (publ) | -69.96 Million SEK | -158.372% |
| SynAct Pharma AB | -224.49 Million SEK | 19.48% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -309.193% |
| BioInvent International AB (publ) | -369.94 Million SEK | 51.137% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -654.625% |
| Alzinova AB (publ) | -16.52 Million SEK | -994.087% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 28.677% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -2727.436% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -62.978% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -1462.9% |